It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

NVF IPO Exits: Our successes 

Since its foundation in 1996, the Novartis Venture Fund has actively supported nearly 40 of its portfolio companies to access the public capital markets like the NASDAQ through a variety of transactions including initial public offerings, as well as reverse mergers, some of which resulted in subsequent acquisitions by large international pharmaceutical companies. 


The list of NVF IPO exits
 

Acorda Therapeutics

Acorda Therapeutics completed its initial public offering (NASDAQ: ACOR) in 2006.

Aeglea Biotherapeutics

Aeglea Biotherapeutics completed its initial public offering (NASDAQ: AGLE) in 2016.

Aerpio Therapeutics

Aerpio Therapeutics completed its initial public offering (NASDAQ:ARPO) in 2017.

Aileron Therapeutics

Aileron Therapeutics completed its initial public offering (NASDAQ) in 2017.

Akebia Therapeutics

Akebia Therapeutics completed its initial public offering (NASDAQ: AKBA) in 2014.

Akouos

Akouos completed its initial public offering (NASDAQ: AKUS) in 2020 and was acquired by Lilly in 2022.

Altimmune, Inc.

Altimmune, Inc. completed a reverse merger into PharmAthene, Inc. (NASDAQ: ALT) and became publicly listed in 2017.

Annexon

Annexon completed its initial public offering (NASDAQ:ANNX) in 2020.

Adicet Bio

Adicet Bio completed a reverse merger into resTORbio and became publicly listed (NASDAQ: ACET) in 2020.

Bicycle Therapeutics

Bicycle Therapeutics completed its initial public offering (NASDAQ: BCYC) in 2019.

BioNano Genomics

BioNano Genomics completed its initial public offering (NASDAQ: BNGO) in 2018.

Celladon

Celladon completed its initial public offering (NASDAQ: CLDN) in 2014.

Cellerix

Cellerix completed a reverse merger into Tigenix BV and became publicly listed (NYSE: TIG) in 2011.

CombinatorRx

CombinatorRx completed its initial public offering (NASDAQ: CRXX) in 2005.

Cytos Biotechnology

Cytos Biotechnology completed its initial public offering (SWX: CYTN) in 2002.

Evolva Holding

Evolva Holding completed a reverse merger into Arpida AG and became publicly listed (SIX: EVE) in 2010.

Eyetech Pharmaceuticals

Eyetech Pharmaceuticals completed its public offering (NASDAQ: EYET) in 2004 and was acquired by Valeant in 2012.

Forma Therapeutics

Forma Therapeutics completed its initial public offering (NASDAQ: FMTX) in 2020 and was acquired by Novo Nordisk in 2022.

Galera Therapeutics

Galera Therapeutics completed its initial public offering (NASDAQ:GRTX) in 2019.

Gensight Biologics

Gensight Biologics completed its initial public offering (Euronext) in 2016.

Idenix Pharmaceuticals

Idenix Pharmaceuticals completed its initial public offering (NASDAQ: IDIX) in 2004 and was acquired by Merck in 2014.

Infinity Pharmaceuticals

Infinity Pharmaceuticals completed a reverse merger into Discovery Partners, Inc. and became publicly listed (NASDAQ: INFI) in 2006.

IsoTis OrthoBiologics

IsoTis OrthoBiologics completed its initial public offering (SWX: ISON) in 2000.

Merus 

Merus completed its initial public offering ((NASDAQ) in 2016.

Nabriva 

Nabriva completed its initial public offering (NASDAQ: NBRV) in 2015.

Neovacs 

Neovacs completed its initial public offering (Alternext Paris: ALNEV) in 2010.

Oculis 

Oculis completed a merger with EBAC, a Special Purpose Acquisition Company, and became publicly listed (NASDAQ: OCS) in 2023.

PharmAbcine 

PharmAbcine Inc. completed its initial public offering (KOSDAQ) in 2018.

Qurient 

Qurient completed its initial public offering (KOSDAQ: 115180) in 2016.

Ra Pharmaceuticals

Ra Pharmaceuticals completed its initial public offering (NASDAQ: RARX) in 2016 and was acquired by UCB in 2019.

Renovacor 

Renovacor completed a public listing via a merger with Chardan Healthcare Acquisition 2 Corp., a Special Purpose Acquisition Company, became publicly listed (NASDAQ: RCOR) in 2021 and was acquired by Rocket Pharmaceuticals in 2022.

Silence Therapeutics 

Silence Therapeutics completed its initial public offering (LON: SLN) in 2005.

Sirtris Pharmaceuticals 

Sirtris Pharmaceuticals completed its initial public offering (NASDAQ: SIRT) in 2007 and was acquired by GlaxoSmithKline in 2008.

Speedel Holding 

Speedel Holding completed its initial public offering (SWX: SPPN) in 2005 and was acquired by Novartis in 2008.

Theravance 

Theravance completed its initial public offering (NASDAQ: THRX) in 2004.

Tokai Pharmaceuticals 

Tokai Pharmaceuticals completed its initial public offering (NASDAQ: TKAI) in 2014.

Torrey Pines Therapeutics 

Torrey Pines Therapeutics completed a reverse merger into Axonyx and became publicly listed (NASDAQ: TPTX) in 2006.

Tscan 

Tscan completed its initial public offering (NASDAQ:TCRX) in 2021.

Xenoport 

Xenoport completed its initial public offering (NASDAQ: XNPT) in 2005.

Our investment team has proven experience

With successful backgrounds in medicine, science, legal, investment, and business development, our team has expertise in bringing exciting new drugs and treatments to patients all over the world.

Learn about our achievements in M&A

The NVF team has developed exit strategies that have steered 29 life science companies, so far, to successful mergers and acquisitions.